Apjohn Ventures

Tetra Therapeutics Inc. is a clinical-stage biotechnology company focused on developing pharmaceutical drugs that target phosphodiesterase (PDE) subtype inhibitors for various neurological and non-neurological disorders. The company is advancing BPN14770, a novel therapeutic agent designed to enhance synaptic actions in the brain's neurons, which is particularly relevant for conditions affecting memory and cognition, such as Alzheimer's disease, schizophrenia, and developmental disabilities. Tetra Therapeutics aims to create effective treatments for patients suffering from Alzheimer's, other dementias, traumatic brain injury, and psychiatric disorders. Founded in 2011 and based in Grand Rapids, Michigan, the company was previously known as Tetra Discovery Partners and rebranded in August 2019. Tetra Therapeutics has established a strategic collaboration with Shionogi & Co., Ltd., and as of July 2020, operates as a subsidiary of Shionogi.

Asterand Bioscience is a leading global provider of high-quality human tissue and human tissue-based research solutions, primarily aimed at drug discovery scientists. Established in 2006 through the merger of Asterand, a human tissue biorepository, and Pharmagene, a drug discovery company, Asterand has a strong heritage in human tissue procurement and characterization. The company focuses on accelerating the identification and validation of drug targets while enhancing the selection of drug candidates to increase the likelihood of clinical success. With offices in Detroit, Michigan, and Royston, United Kingdom, Asterand serves pharmaceutical, biotechnology, and diagnostic companies, as well as academic institutions, offering comprehensive research services that span from target identification to compound evaluation and drug safety.